Drugs / PF-07202954
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04857437 | May → Sep 2021 | NAFLD1, fibrotic liver disease | Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07202954 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04857437 ↗ |
| Route | Oral | “oral doses” NCT04857437 ↗ |